Thomas Jaenisch
Concepts (295)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zika Virus Infection | 28 | 2025 | 165 | 5.990 |
Why?
| | Dengue | 25 | 2024 | 80 | 5.530 |
Why?
| | Zika Virus | 24 | 2025 | 128 | 3.940 |
Why?
| | Pregnancy Complications, Infectious | 12 | 2022 | 390 | 2.140 |
Why?
| | Disease Outbreaks | 9 | 2024 | 387 | 1.600 |
Why?
| | Microcephaly | 9 | 2023 | 97 | 1.520 |
Why?
| | Dengue Virus | 12 | 2024 | 52 | 1.140 |
Why?
| | Epidemics | 4 | 2023 | 89 | 1.100 |
Why?
| | Communicable Diseases | 6 | 2024 | 159 | 1.000 |
Why?
| | Seroepidemiologic Studies | 15 | 2024 | 165 | 0.960 |
Why?
| | Malaria | 3 | 2022 | 63 | 0.940 |
Why?
| | Antibodies, Viral | 14 | 2024 | 624 | 0.830 |
Why?
| | Congenital Abnormalities | 2 | 2021 | 88 | 0.800 |
Why?
| | Chikungunya Fever | 8 | 2024 | 79 | 0.800 |
Why?
| | Brazil | 15 | 2024 | 167 | 0.790 |
Why?
| | Malaria, Falciparum | 3 | 2012 | 27 | 0.770 |
Why?
| | Protein Array Analysis | 2 | 2020 | 57 | 0.770 |
Why?
| | Masks | 1 | 2022 | 63 | 0.760 |
Why?
| | Public Health | 6 | 2025 | 579 | 0.750 |
Why?
| | Endpoint Determination | 2 | 2018 | 77 | 0.720 |
Why?
| | Anemia | 3 | 2022 | 170 | 0.680 |
Why?
| | Dengue Vaccines | 2 | 2018 | 10 | 0.650 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2019 | 17 | 0.610 |
Why?
| | Politics | 3 | 2025 | 98 | 0.600 |
Why?
| | Severe Dengue | 5 | 2022 | 10 | 0.590 |
Why?
| | Latin America | 8 | 2024 | 93 | 0.560 |
Why?
| | Humans | 86 | 2025 | 136764 | 0.550 |
Why?
| | Plasmodium falciparum | 3 | 2019 | 30 | 0.540 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 1044 | 0.530 |
Why?
| | Parasitemia | 2 | 2021 | 13 | 0.520 |
Why?
| | Biomedical Research | 3 | 2025 | 688 | 0.500 |
Why?
| | Child Health | 1 | 2016 | 154 | 0.450 |
Why?
| | Capital Financing | 1 | 2013 | 8 | 0.430 |
Why?
| | Prospective Studies | 16 | 2023 | 7572 | 0.420 |
Why?
| | Peptides | 1 | 2019 | 979 | 0.400 |
Why?
| | Information Dissemination | 2 | 2025 | 215 | 0.390 |
Why?
| | Young Adult | 22 | 2024 | 13129 | 0.390 |
Why?
| | Child | 25 | 2024 | 21822 | 0.370 |
Why?
| | Genetic Variation | 2 | 2017 | 985 | 0.370 |
Why?
| | Chikungunya virus | 6 | 2023 | 80 | 0.360 |
Why?
| | Sexual Partners | 2 | 2024 | 186 | 0.360 |
Why?
| | Mosquito Vectors | 4 | 2019 | 30 | 0.350 |
Why?
| | Emergency Responders | 2 | 2021 | 36 | 0.340 |
Why?
| | Female | 40 | 2024 | 72787 | 0.340 |
Why?
| | Bayes Theorem | 2 | 2022 | 404 | 0.330 |
Why?
| | Hemoglobins | 2 | 2022 | 353 | 0.320 |
Why?
| | Aedes | 4 | 2019 | 65 | 0.320 |
Why?
| | Alphavirus | 2 | 2019 | 21 | 0.320 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2021 | 182 | 0.320 |
Why?
| | Pregnancy | 13 | 2022 | 6728 | 0.310 |
Why?
| | Adolescent | 21 | 2024 | 21382 | 0.310 |
Why?
| | Alphavirus Infections | 2 | 2019 | 44 | 0.310 |
Why?
| | Delivery of Health Care | 1 | 2016 | 934 | 0.310 |
Why?
| | Pandemics | 5 | 2025 | 1613 | 0.310 |
Why?
| | Causality | 3 | 2024 | 126 | 0.300 |
Why?
| | Serologic Tests | 4 | 2021 | 54 | 0.290 |
Why?
| | Asia | 5 | 2023 | 70 | 0.290 |
Why?
| | Adult | 26 | 2024 | 37630 | 0.280 |
Why?
| | Viremia | 3 | 2024 | 138 | 0.280 |
Why?
| | Male | 31 | 2024 | 67309 | 0.280 |
Why?
| | Immunity, Humoral | 2 | 2019 | 116 | 0.270 |
Why?
| | Incidence | 7 | 2020 | 2792 | 0.260 |
Why?
| | Virus Diseases | 2 | 2019 | 211 | 0.260 |
Why?
| | Infant, Newborn | 12 | 2022 | 6033 | 0.260 |
Why?
| | Infant | 11 | 2021 | 9398 | 0.250 |
Why?
| | Pneumonia | 1 | 2012 | 635 | 0.250 |
Why?
| | Cluster Analysis | 2 | 2019 | 497 | 0.250 |
Why?
| | Meta-Analysis as Topic | 2 | 2024 | 186 | 0.240 |
Why?
| | Sexually Transmitted Diseases, Viral | 2 | 2024 | 10 | 0.240 |
Why?
| | Africa South of the Sahara | 2 | 2022 | 48 | 0.230 |
Why?
| | Mass Media | 1 | 2025 | 42 | 0.230 |
Why?
| | Child, Preschool | 14 | 2024 | 11000 | 0.230 |
Why?
| | Fever | 2 | 2023 | 306 | 0.220 |
Why?
| | Malaria Vaccines | 2 | 2019 | 8 | 0.220 |
Why?
| | Middle Aged | 17 | 2024 | 33228 | 0.220 |
Why?
| | Viral Nonstructural Proteins | 2 | 2018 | 65 | 0.220 |
Why?
| | Arbovirus Infections | 1 | 2024 | 21 | 0.220 |
Why?
| | Arboviruses | 2 | 2024 | 16 | 0.220 |
Why?
| | South America | 1 | 2024 | 59 | 0.220 |
Why?
| | Severity of Illness Index | 2 | 2014 | 2822 | 0.220 |
Why?
| | Semantics | 1 | 2024 | 92 | 0.210 |
Why?
| | Linear Models | 2 | 2023 | 846 | 0.210 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2021 | 105 | 0.200 |
Why?
| | O'nyong-nyong Virus | 2 | 2019 | 4 | 0.200 |
Why?
| | Attitude of Health Personnel | 1 | 2011 | 1163 | 0.200 |
Why?
| | Risk Factors | 10 | 2022 | 10326 | 0.200 |
Why?
| | Toxoplasmosis | 2 | 2019 | 40 | 0.190 |
Why?
| | Oligohydramnios | 1 | 2022 | 12 | 0.190 |
Why?
| | Personal Protective Equipment | 1 | 2022 | 52 | 0.190 |
Why?
| | Ebolavirus | 1 | 2022 | 35 | 0.190 |
Why?
| | Mosquito Control | 2 | 2014 | 28 | 0.190 |
Why?
| | Cytokines | 3 | 2021 | 2083 | 0.190 |
Why?
| | Social Media | 1 | 2025 | 157 | 0.190 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 285 | 0.190 |
Why?
| | RNA, Viral | 4 | 2022 | 654 | 0.190 |
Why?
| | Vietnam | 4 | 2024 | 28 | 0.190 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 116 | 0.190 |
Why?
| | Algorithms | 2 | 2022 | 1689 | 0.190 |
Why?
| | World Health Organization | 4 | 2018 | 123 | 0.190 |
Why?
| | Endemic Diseases | 3 | 2024 | 32 | 0.190 |
Why?
| | Research Design | 3 | 2024 | 1127 | 0.190 |
Why?
| | Cohort Studies | 8 | 2025 | 5701 | 0.180 |
Why?
| | Tanzania | 2 | 2012 | 58 | 0.180 |
Why?
| | Epitopes | 2 | 2020 | 477 | 0.180 |
Why?
| | Chemokine CXCL10 | 1 | 2021 | 39 | 0.170 |
Why?
| | Health Policy | 2 | 2014 | 385 | 0.170 |
Why?
| | Risk | 5 | 2021 | 908 | 0.170 |
Why?
| | Epitope Mapping | 1 | 2020 | 62 | 0.170 |
Why?
| | Transients and Migrants | 1 | 2020 | 24 | 0.170 |
Why?
| | Prevalence | 4 | 2021 | 2711 | 0.160 |
Why?
| | Rubella virus | 1 | 2019 | 7 | 0.160 |
Why?
| | Parvovirus B19, Human | 1 | 2019 | 3 | 0.160 |
Why?
| | Emigration and Immigration | 1 | 2020 | 46 | 0.160 |
Why?
| | Toxoplasma | 1 | 2019 | 42 | 0.160 |
Why?
| | Case-Control Studies | 4 | 2021 | 3540 | 0.160 |
Why?
| | Hydrocephalus | 1 | 2020 | 106 | 0.160 |
Why?
| | Hospitalization | 2 | 2020 | 2183 | 0.160 |
Why?
| | Biomarkers | 5 | 2023 | 4143 | 0.160 |
Why?
| | Phylogeny | 3 | 2019 | 902 | 0.150 |
Why?
| | Diagnosis, Differential | 3 | 2021 | 1481 | 0.150 |
Why?
| | Antibodies, Protozoan | 1 | 2019 | 36 | 0.150 |
Why?
| | Cytomegalovirus | 1 | 2019 | 157 | 0.150 |
Why?
| | Viral Load | 1 | 2021 | 464 | 0.150 |
Why?
| | Africa | 2 | 2019 | 108 | 0.150 |
Why?
| | Automation | 1 | 2019 | 95 | 0.150 |
Why?
| | Violence | 1 | 2021 | 257 | 0.150 |
Why?
| | Peptide Library | 1 | 2019 | 88 | 0.150 |
Why?
| | Premature Birth | 1 | 2022 | 331 | 0.150 |
Why?
| | Communicable Diseases, Emerging | 1 | 2018 | 35 | 0.150 |
Why?
| | Serotyping | 1 | 2018 | 32 | 0.150 |
Why?
| | Genotype | 4 | 2017 | 1914 | 0.150 |
Why?
| | Serum | 1 | 2018 | 59 | 0.140 |
Why?
| | Phosphoinositide Phospholipase C | 1 | 2017 | 5 | 0.140 |
Why?
| | C-Reactive Protein | 1 | 2020 | 408 | 0.140 |
Why?
| | Global Health | 3 | 2019 | 385 | 0.140 |
Why?
| | Maternal-Fetal Exchange | 1 | 2018 | 165 | 0.140 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2017 | 37 | 0.140 |
Why?
| | Delphi Technique | 1 | 2018 | 273 | 0.130 |
Why?
| | Peptide Mapping | 1 | 2017 | 64 | 0.130 |
Why?
| | Longitudinal Studies | 4 | 2022 | 2829 | 0.130 |
Why?
| | Blood Donors | 1 | 2018 | 103 | 0.130 |
Why?
| | Spatio-Temporal Analysis | 3 | 2025 | 34 | 0.130 |
Why?
| | Sequence Homology | 1 | 2016 | 40 | 0.130 |
Why?
| | Caribbean Region | 3 | 2020 | 28 | 0.130 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 2021 | 851 | 0.120 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2017 | 202 | 0.120 |
Why?
| | Viral Envelope Proteins | 1 | 2016 | 84 | 0.120 |
Why?
| | Clinical Protocols | 1 | 2016 | 267 | 0.120 |
Why?
| | Antigens | 1 | 2017 | 357 | 0.120 |
Why?
| | Serogroup | 3 | 2021 | 44 | 0.110 |
Why?
| | Antibodies | 1 | 2017 | 410 | 0.110 |
Why?
| | Models, Theoretical | 1 | 2018 | 575 | 0.110 |
Why?
| | Antigens, Viral | 2 | 2018 | 178 | 0.110 |
Why?
| | Fluid Therapy | 1 | 2016 | 147 | 0.110 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3264 | 0.110 |
Why?
| | Environment | 1 | 2016 | 357 | 0.110 |
Why?
| | European Union | 1 | 2013 | 12 | 0.110 |
Why?
| | Residence Characteristics | 1 | 2017 | 349 | 0.110 |
Why?
| | Mental Health | 1 | 2020 | 716 | 0.110 |
Why?
| | Animals | 11 | 2019 | 36823 | 0.110 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2021 | 842 | 0.100 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 809 | 0.100 |
Why?
| | Immunoglobulin M | 3 | 2021 | 289 | 0.100 |
Why?
| | Disease Management | 1 | 2016 | 624 | 0.090 |
Why?
| | Peru | 2 | 2021 | 58 | 0.090 |
Why?
| | Sensitivity and Specificity | 4 | 2019 | 1935 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5106 | 0.090 |
Why?
| | Virology | 1 | 2010 | 24 | 0.080 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2010 | 42 | 0.080 |
Why?
| | Indian Ocean Islands | 1 | 2010 | 1 | 0.080 |
Why?
| | Cross Reactions | 2 | 2022 | 133 | 0.080 |
Why?
| | Inflammation | 1 | 2021 | 2834 | 0.080 |
Why?
| | Neutralization Tests | 2 | 2021 | 75 | 0.080 |
Why?
| | Family Characteristics | 2 | 2021 | 189 | 0.080 |
Why?
| | Age Factors | 2 | 2020 | 3284 | 0.080 |
Why?
| | Rural Health | 1 | 2010 | 79 | 0.080 |
Why?
| | Mass Screening | 1 | 2018 | 1267 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 2184 | 0.080 |
Why?
| | Kinetics | 2 | 2024 | 1663 | 0.080 |
Why?
| | Age Distribution | 1 | 2010 | 389 | 0.080 |
Why?
| | Americas | 2 | 2019 | 28 | 0.070 |
Why?
| | Sexual Behavior | 2 | 2024 | 483 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1507 | 0.070 |
Why?
| | Coinfection | 2 | 2019 | 137 | 0.070 |
Why?
| | Focus Groups | 1 | 2011 | 515 | 0.070 |
Why?
| | Surveys and Questionnaires | 2 | 2011 | 5742 | 0.070 |
Why?
| | Genome, Viral | 2 | 2019 | 143 | 0.070 |
Why?
| | Antigens, Protozoan | 1 | 2007 | 24 | 0.070 |
Why?
| | Risk Assessment | 1 | 2017 | 3432 | 0.070 |
Why?
| | High-Throughput Screening Assays | 2 | 2020 | 158 | 0.070 |
Why?
| | Prenatal Care | 2 | 2019 | 288 | 0.070 |
Why?
| | Logistic Models | 1 | 2012 | 2067 | 0.070 |
Why?
| | Immunoglobulin G | 2 | 2021 | 887 | 0.060 |
Why?
| | Urbanization | 2 | 2019 | 29 | 0.060 |
Why?
| | Microsatellite Repeats | 1 | 2007 | 168 | 0.060 |
Why?
| | Quarantine | 1 | 2025 | 30 | 0.060 |
Why?
| | Tropical Climate | 2 | 2016 | 19 | 0.060 |
Why?
| | Biosurveillance | 1 | 2024 | 1 | 0.060 |
Why?
| | Aged | 6 | 2023 | 23794 | 0.060 |
Why?
| | Common Data Elements | 1 | 2024 | 14 | 0.060 |
Why?
| | Platelet Count | 1 | 2024 | 85 | 0.060 |
Why?
| | Biological Specimen Banks | 1 | 2025 | 102 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 659 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1462 | 0.050 |
Why?
| | Europe | 1 | 2025 | 413 | 0.050 |
Why?
| | Forecasting | 1 | 2025 | 386 | 0.050 |
Why?
| | Checklist | 1 | 2024 | 93 | 0.050 |
Why?
| | Bangladesh | 1 | 2023 | 56 | 0.050 |
Why?
| | Altitude | 1 | 2007 | 485 | 0.050 |
Why?
| | Data Interpretation, Statistical | 1 | 2024 | 363 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2024 | 275 | 0.050 |
Why?
| | Burkina Faso | 1 | 2021 | 7 | 0.050 |
Why?
| | Middle East | 1 | 2021 | 15 | 0.050 |
Why?
| | Colostrum | 1 | 2021 | 3 | 0.050 |
Why?
| | Venezuela | 1 | 2021 | 8 | 0.050 |
Why?
| | Publication Bias | 1 | 2021 | 41 | 0.040 |
Why?
| | Pregnancy Trimesters | 1 | 2021 | 19 | 0.040 |
Why?
| | Microspheres | 1 | 2021 | 137 | 0.040 |
Why?
| | Colorado | 2 | 2021 | 4518 | 0.040 |
Why?
| | Blood | 1 | 2021 | 107 | 0.040 |
Why?
| | Amniotic Fluid | 1 | 2021 | 96 | 0.040 |
Why?
| | Immunoassay | 1 | 2021 | 113 | 0.040 |
Why?
| | Disease Progression | 2 | 2020 | 2750 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2021 | 346 | 0.040 |
Why?
| | Parturition | 1 | 2020 | 71 | 0.040 |
Why?
| | Immunomodulation | 1 | 2021 | 98 | 0.040 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 97 | 0.040 |
Why?
| | Disease Reservoirs | 1 | 2019 | 21 | 0.040 |
Why?
| | Genes, Viral | 1 | 2019 | 88 | 0.040 |
Why?
| | Pregnancy Outcome | 1 | 2022 | 412 | 0.040 |
Why?
| | Geography, Medical | 1 | 2019 | 11 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5423 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2024 | 15504 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1692 | 0.040 |
Why?
| | Pathology, Molecular | 1 | 2019 | 27 | 0.040 |
Why?
| | Zoonoses | 1 | 2019 | 33 | 0.040 |
Why?
| | Primates | 1 | 2019 | 125 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2021 | 1059 | 0.040 |
Why?
| | Computer Simulation | 1 | 2022 | 973 | 0.040 |
Why?
| | Bolivia | 1 | 2018 | 65 | 0.040 |
Why?
| | Viral Plaque Assay | 1 | 2017 | 31 | 0.040 |
Why?
| | Volunteers | 1 | 2018 | 29 | 0.040 |
Why?
| | United States | 2 | 2025 | 14691 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2021 | 7585 | 0.030 |
Why?
| | Basic Reproduction Number | 1 | 2017 | 5 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 266 | 0.030 |
Why?
| | Time Factors | 2 | 2020 | 6806 | 0.030 |
Why?
| | Parent-Child Relations | 1 | 2020 | 268 | 0.030 |
Why?
| | Poliovirus Vaccines | 1 | 2017 | 6 | 0.030 |
Why?
| | Binding Sites, Antibody | 1 | 2017 | 42 | 0.030 |
Why?
| | Culicidae | 1 | 2017 | 37 | 0.030 |
Why?
| | Molecular Epidemiology | 1 | 2017 | 67 | 0.030 |
Why?
| | Iron | 1 | 2019 | 312 | 0.030 |
Why?
| | Cell Surface Display Techniques | 1 | 2017 | 12 | 0.030 |
Why?
| | Phylogeography | 1 | 2017 | 54 | 0.030 |
Why?
| | Climate Change | 1 | 2019 | 182 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2017 | 189 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 974 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1614 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2021 | 651 | 0.030 |
Why?
| | Capsid Proteins | 1 | 2017 | 94 | 0.030 |
Why?
| | Pacific Islands | 1 | 2015 | 3 | 0.030 |
Why?
| | Enterovirus | 1 | 2017 | 86 | 0.030 |
Why?
| | Bacterial Infections | 1 | 2018 | 250 | 0.030 |
Why?
| | Immunization | 1 | 2018 | 411 | 0.030 |
Why?
| | Inpatients | 1 | 2020 | 496 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 729 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 358 | 0.030 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2015 | 137 | 0.030 |
Why?
| | Models, Statistical | 1 | 2019 | 667 | 0.030 |
Why?
| | Hospitals | 1 | 2020 | 685 | 0.030 |
Why?
| | Shock | 1 | 2016 | 95 | 0.030 |
Why?
| | Travel | 1 | 2015 | 130 | 0.030 |
Why?
| | Blood Vessels | 1 | 2016 | 187 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2014 | 145 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2017 | 2136 | 0.020 |
Why?
| | Quality Control | 1 | 2013 | 171 | 0.020 |
Why?
| | Rain | 1 | 2013 | 47 | 0.020 |
Why?
| | Antiviral Agents | 1 | 2018 | 739 | 0.020 |
Why?
| | Cell Line | 1 | 2018 | 2837 | 0.020 |
Why?
| | Thrombocytopenia | 1 | 2014 | 198 | 0.020 |
Why?
| | Computational Biology | 1 | 2017 | 643 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4013 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1430 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 1428 | 0.020 |
Why?
| | Temperature | 1 | 2013 | 675 | 0.020 |
Why?
| | Hemorrhage | 1 | 2014 | 721 | 0.020 |
Why?
| | Vaccination | 1 | 2017 | 1376 | 0.020 |
Why?
| | Merozoite Surface Protein 1 | 1 | 2007 | 4 | 0.020 |
Why?
| | Zimbabwe | 1 | 2007 | 58 | 0.020 |
Why?
| | Databases, Factual | 1 | 2013 | 1351 | 0.020 |
Why?
| | Protozoan Proteins | 1 | 2007 | 82 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2014 | 1571 | 0.020 |
Why?
| | Mutation | 1 | 2017 | 3946 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2018 | 10744 | 0.010 |
Why?
|
|
Jaenisch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|